Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR
Holding BNR?
Track your performance easily
BNR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.62 - $9.98
Previous Close$6.58
Volume13.78K
Average Volume (3M)34.72K
Market Cap
$65.57M
Enterprise ValueN/A
Total Cash (Recent Filing)$615.10M
Total Debt (Recent Filing)$12.32M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.78
Shares Outstanding10,258,726
10 Day Avg. Volume77,666
30 Day Avg. Volume34,720
Standard Deviation0.26
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.09
Price to Sales (P/S)0.88
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Burning Rock Biotech News
PremiumCompany Announcements
Burning Rock Biotech’s Strategic Growth and Financial Results
PremiumCompany Announcements
Burning Rock Biotech Schedules AGM for December 2024
PremiumCompany Announcements
Burning Rock Biotech Announces Executive Changes
PremiumCompany Announcements
Burning Rock Biotech Strengthens Audit Committee
PremiumCompany Announcements
Burning Rock Biotech Announces Board Resignation
PremiumCompany Announcements
Burning Rock Biotech Q2 Earnings and Strategic ShiftOwnership Overview
―
Insiders
4.33% Mutual Funds
13.47% Other Institutional Investors
82.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $2.62 and its highest was $9.98 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Currently, no data Available
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Burning Rock Biotech Ltd. released its earnings results on Dec 04, 2024. The company reported -$0.048 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.048.
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,232,740 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Burning Rock Biotech Ltd. reported an EPS of -$0.048 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.607%.
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Among the largest hedge funds holding Burning Rock Biotech Ltd.’s share is Bridgewater Associates, LP. It holds Burning Rock Biotech Ltd.’s shares valued at N/A.
---
Burning Rock Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.26%
12-Months-Change
Fundamentals
Return on Equity
-56.29%
Trailing 12-Months
Asset Growth
-12.13%
Trailing 12-Months
Company Description
Burning Rock Biotech Ltd.
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.
---
BNR Company Deck
---
BNR Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive financial turnaround with significant improvements in sales efficiency, profitability, and in-hospital revenue growth. Despite industry challenges, the company demonstrated a strong cash position and strategic adaptability.Read More>---
Technical Analysis
---